Be Prepared to Dispense Alternatives to Usual COVID-19 Meds
October 2021
Shortages of tocilizumab (Actemra) mean you'll see more orders for other COVID-19 treatments.
Tocilizumab has been the go-to add-on to steroids (dexamethasone, etc) for COVID-19. It's because this "IL-6 inhibitor" has the strongest evidence for reducing mortality.
But tocilizumab supplies are low. And it may need to be reserved for other uses where tocilizumab is the only treatment.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote